Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (erosive GERD) or ulcerations (complicated GERD) can be very painful.
Clinical Stage Pharma
Developing small molecules for the treatment of gastric acid related diseases.
Cinclus Pharma
The Next Leap Forward
Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (PCABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.
Our lead asset
Linaprazan glurate
Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials have been successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.
In the spotlight
Cinclus Pharma invites to KOL event
Cinclus Pharma Holding AB (publ) will host a virtual event featuring Professor Prateek Sharma from the Cancer Center in Kansas City, to provide deeper insights on the current treatment landscape and the unmet medical need among patients with erosive…
Cinclus Pharma’s CEO Christer Ahlberg in an interview with Redeye about the Phase III study and the Q3 report
Redeye has interviewed Cinclus Pharma’s CEO, Christer Ahlberg, about the company’s recently initiated Phase III study with linaprazan glurate and the company’s Q3 report.
Watch the full presentation from Redeye Investor Forum
Here you can watch the full presentation by CEO Christer Ahlberg about Cinclus Pharma and the development of linaprazan glurate, presented at the Redeye Investor Forum
"Cinclus Pharma wants to accomplish a paradigm shift in the treatment of acid-related diseases. We will do this by registering and launching our effective PCAB linaprazan glurate and making it available worldwide."
CHRISTER AHLBERG
CEO CINCLUS PHARMA